The crystal structure of ES reveals a helix stabilized by man endostatin (hES), whereas the mutants mES3.1 and AP-ES3.1 did not inhibit migration of endothelial cells in two disulfide bonds which result in the hydrophobic side chains of phenylalanine residues 162 and 165 being response to VEGF 165 , as predicted by the binding assay ( Figure 1C ). presented to the outside of the molecule (Hohenester et al., 1998). We hypothesized that these side chains During a survey of various cell lines that bound ES, we found that both inner medullary collecting duct (IMCD) might form a high-affinity binding site in the hydrophobic environment of an ES receptor, and therefore changed ( Figure 1B ) and Madin-Darby canine kidney (MDCK) cells bound AP-ES. Since ES has recently been isolated these residues to alanines in an attempt to decrease the affinity for the receptor. The wild-type mouse endostatin in renal ureteric bud culture supernatants (J. Barasch, personal communications), we hypothesized that it may (mES) and the mutant ES (mES3.1) were generated in soluble form in Pichia and as an AP-tagged form in mamplay a role in renal-epithelial cell branching morphogenesis. Figure 1D shows that mES indeed inhibited branchmalian cells (wild type referred to as AP-ES and mutant AP-ES3.1) ( Figure 1A ). We found that AP-ES, but not ing process formation of IMCD cells in response to both hepatocyte growth factor (HGF) and epidermal growth AP-ES3.1, bound endothelial cells specifically ( Figure  1B) . Also, mES competed for AP-ES binding, whereas factor (EGF). The morphology of branching process formation is depicted in Figure 1E Figure 3C ), and L (fibroblast) cells. Retroviral pools from a HUVE and HRME cDNA library were used to infect NIH 3T3 cells and expression cloning performed as described in Experimental Procedures. The clone that induced in situ binding of AP-ES was a 3.5 kb cDNA (likely of HRME origin) whose sequence matched identically with the region 205 to 3718 bases of the human glypican-4 sequence (Genbank accession number NM001448). To confirm that glypican-4 cDNA was indeed giving AP-ES binding, we infected NIH 3T3 cells with a retrovirus carrying the glypican-4 cDNA, and these cells (g4) showed purple staining ( Figure 3D) . Glypican-4, or K-glypican as it was originally described, is highly expressed in developing brains and is thought to be the predominant glypican expressed in renal tubular cells (Watanabe et al., 1995) . Glypican-1 is thought to be the major glypican in endothelial cells Thus, these results demonstrate that mES binds with high-affinity to only certain saccharides, suggesting that in vivo ES binding to glypican at the cell surface is mediated primarily through the saccharide portion of glypican.
To confirm and extend these results, the hexasaccharide species that binds with high-affinity was purified (Figures 5B and 5C ). Importantly, this saccharide was not ( Figure 6D ). However, when these cells were infected with retroviruses carrying antisense glypican-1 cDNA, selected with heat-denatured mES or with mES3.1 (that does not bind glypican), indicating that the observed we found that VEGF 165 was unable to induce migration of endothelial cells, consistent with the fact that VEGF 165 binder is highly specific for intact, native mES (data not shown). Sequence analysis of this saccharide using requires glypicans to bind to its receptor and trigger 
ES Cell Surface Binding
We utilized an AP-tag to label ES, after unsuccessful attempts at iodination. This molecule was functional in a migration assay at ng/ml levels, similar to our previously described Pichia-derived mES and hES ( Figure 1C ). We designed a two amino acid mutant (ES3.1) based on ES's crystal structure that might affect function. This mutant was produced in mammalian cells (AP-ES3.1) and in soluble form in Pichia (mES3.1). It bound heparin (eluting at 0.2-0.3 M NaCl for mES3.1 versus 0.3-0.6 M NaCl for mES), suggesting that it shared some conformational properties with wild-type ES. However, it was functionally inactive, did not show cell surface binding to endothelial cells or glypican expressing NIH 3T3 cells, and did not bind to the ES hexasaccharide binder (ϮDD-5). These data confirm the importance of the two phenylalanines for ES binding and function, illustrating cm 293-GPG dishes. About 18 ml of virus supernatant obtained from three such plates was concentrated to 1 ml using ultracentrifugation domains of KDR (VEGF receptor) is described elsewhere (Zeng and Mukhopadhyay, our unpublished data). (Ory et al., 1996) and used to infect 2 ϫ 10 6 NIH 3T3 cells. This procedure routinely gave us greater than 95% transduction efficiency. Seventy-two hours after retroviral transduction, we split the Expression and Purification of Recombinant Proteins cells into 2 plates; one was used for in situ hybridization, whereas Recombinant mouse endostatin (mES) and human endostatin (hES) the cells from other plate were distributed into a 96-well plate. After were expressed and purified from Pichia Pastoris as described preachieving confluence, cells were spread into two duplicate 96-well viously (Dhanabal et al., 1999a; Dhanabal et al., 1999c). Mutant mES plates. One plate was used for in situ hybridization. Cells from the cDNA was excised from pAP-ES3.1 and cloned into pPICZ␣A and wells corresponding to positive wells were pooled and distributed mutant endostatin (mES3.1) was also generated in Pichia. AP-ES into a 48-well plate, and the process was repeated three times, at and AP-ES3.1 were produced in mammalian cells by transient transwhich time more than 90% of cells were positive for AP staining. fection of their cDNAs into 293T cells. The supernatant was collected
The retroviral inserts were rescued by PCR (long-range PCR kit, after 4 days, concentrated and quantitated for ES amount by using Boehringer-Manheim) from genomic DNA using primers flanking a Western blot with known amounts of mES. AP activity was deterthe cDNA inserts (5Ј primer 5Ј-AGCCCTCACTCCTTCTCTAG3Ј and mined with known dilutions of AP-ES and a standard curve was 3Ј primer 5Ј-ATGGCGTTACTTAAGCTAGCTTGCCAAACCTAC3Ј) and plotted against AP activity and defined concentrations of AP-ES then sequenced. (data not shown). The curve was linear between AP activities of 0.05 and 1.5. Recombinant heparinase I, II, and III were produced as described previously (Natke et al., 2000) . Anti-angiogenic ATIII was Migration Assay generated from recombinant ATIII as described by O'Reilly et al.
This assay was performed using Transwells 
